32,282 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 32,282 shares of the medical equipment provider’s stock, valued at approximately $2,945,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZBH. Dodge & Cox lifted its holdings in Zimmer Biomet by 1.3% in the fourth quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock valued at $2,113,736,000 after acquiring an additional 290,676 shares during the last quarter. BlackRock Inc. purchased a new stake in Zimmer Biomet in the second quarter valued at $1,344,282,000. State Street Corp lifted its stake in shares of Zimmer Biomet by 2.3% in the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock valued at $795,814,000 after purchasing an additional 195,214 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Zimmer Biomet by 43.2% during the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Zimmer Biomet by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock worth $468,821,000 after purchasing an additional 36,611 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $101.10 on Monday. The company’s 50 day moving average is $93.88 and its two-hundred day moving average is $91.46. The firm has a market cap of $19.28 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 2.74 and a beta of 0.45. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $106.88.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several research analyst reports. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Citigroup cut their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. Robert W. Baird set a $104.00 price target on Zimmer Biomet in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group boosted their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.